Clinigen Group plc Issue of Equity (0614Q)

TIDMCLIN

RNS Number : 0614Q

Clinigen Group plc

16 October 2019

Issue of Equity

Clinigen Group plc (AIM: CLIN, the "Group") announces that it has made an application for the admission to trading on AIM of 369,591 ordinary shares of 0.1 pence each in the Group (the "New Ordinary Shares"). These New Ordinary Shares have been issued to satisfy share options vesting under The Clinigen Group Long Term Incentive Plan and rank pari passu with the existing shares of the Group. Admission to trading on AIM of the New Ordinary Shares is anticipated to occur on 21 October 2019.

At admission the issued share capital of the Group will consist of 132,848,758 ordinary shares, with no shares held in treasury. The total number of voting rights in the Group will therefore be 132,848,758. This figure may be used by shareholders as the denominator to determine if they are required to notify their interests in, or a change to their interests in, the Group under the Disclosure Guidance and Transparency Rules.

-Ends-

Contact details

 
 Clinigen Group plc                                Tel: +44 (0) 1283 495010 
 Shaun Chilton, Group Chief Executive Officer 
 Nick Keher, Group Chief Financial Officer 
 Matt Parrish, Head of Investor Relations 
 
 Numis Securities Limited - Nominated Adviser        Tel: +44 (0) 20 7260 
  & Joint Broker                                             1000 
 James Black / Freddie Barnfield 
 
 RBC Capital Markets - Joint Broker                  Tel: +44 (0) 20 7653 
                                                             4000 
 Marcus Jackson / Elliot Thomas 
 
 Instinctif Partners                                 Tel: +44 (0) 20 7457 
                                                             2020 
 Melanie Toyne-Sewell / Rozi Morris / Phillip 
  Marriage                                      Email: clinigen@instinctif.com

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. The Group has sites in North America, Europe, Africa and Asia Pacific. In October 2018, the Group acquired CSM, a specialist provider of packaging, labelling, warehousing and distribution services, with sites in the US and Europe, and iQone, a specialist pharmaceutical company in Switzerland.

For more information, please visit www.clinigengroup.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

IOEFFFSUMFUSEFS

(END) Dow Jones Newswires

October 16, 2019 05:12 ET (09:12 GMT)

Clinigen (LSE:CLIN)
Historical Stock Chart
From Apr 2024 to May 2024